Surgalign & NuVasive: How they line up in Q1

Medical technology companies Surgalign and NuVasive posted their first quarter financial results for 2023. 

Here is how they compare: 

Surgalign: 

Revenue: $16.7 million

Operating loss: $1.1 million 

Year-over-year revenue dip: $3.9 million

NuVasive: 

Sales: $307.7 million

Operating loss: $1 million

Year-over-year sales increase: $17 million